Influenza disease in older adults

Influenza disease in adults 65 years of age and older:

  • Nearly 90% of influenza-related deaths were in people 65 years of age and older1
    • - Waning immunity due to advancing age places older adults at greater risk of infection2
  • Studies show that people 65 years of age and older:
    • - Do not respond to standard-dose influenza vaccine as well as younger adults2
    • - May be left without sufficient protection with a standard-dose influenza vaccine3

Effectiveness of standard-dose influenza vaccine2

Chart: Effectiveness of standard-dose influenza vaccine by age

"Achieving optimal success in preventing and controlling influenza among the elderly may require more immunogenic vaccines and new strategies."4
– Nichol, et al.

  • To address the medical needs of older adults, vaccines that provide both higher and broader protection may be required2
Back to top

Older adults have a lower immune response to influenza vaccine compared with younger adults2

Observational study of immunogenicity of Fluzone vaccine in younger and older adults5

Chart: Observational study of Fluzone vaccine immunogenicity in younger and older adults
  • In a clinical study of the immunogenicity of Fluzone vaccine, younger adults (range: 18 through 60 years) and older adults (range: ≥ 61 years) were evaluated. Results were obtained after vaccination with a single dose of the 2009-2010 formulation of Fluzone vaccine.5,a Seroconversion defined as either a pre-vaccination hemagglutination inhibition (HI) titer <1:10 and a post-vaccination titer ≥1:40 or a pre-vaccination titer ≥1:10 and a 4-fold increase in post-vaccination titer.5
Back to top

About Fluzone High-Dose vaccine

Fluzone High-Dose vaccine generates a more robust immune response in adults 65 years of age and older.6

Phase III trial of immunogenicity of Fluzone High-Dose vaccine6,a

Chart: Phase III trial of Fluzone High-Dose vaccine immunogenicity

Post-vaccination geometric mean antibody titers (GMTs) in adults 65 years of age and older (Phase III)6

Chart: Post-vaccination geometric mean antibody titers (GMTs)in adults 65 years and older (Phase III)

a The primary endpoint of the study was hemagglutination inhibition (HI) titer 28 days after vaccination. Prespecified statistical superiority criteria required that (1) the lower limit (LL) of the 2-sided 95% CI of the GMT ratio of Fluzone High-Dose vaccine to Fluzone vaccine be greater than 1.50 for at least 2 of the strains, and if 1 strain failed, noninferiority of that strain must be demonstrated (LL>0.67), and that (2) the LL of the 2-sided 95% CI of the seroconversion rate difference between Fluzone High-Dose vaccine and Fluzone vaccine be greater than 10% for at least 2 of the strains, and if 1 strain failed, noninferiority of that strain must be demonstrated (LL>-10%).6

b Seroconversion: paired samples with pre-vaccination HI titer <1:10 and post-vaccination (day 28) titer ≥1:40 or a minimum 4-fold increase for those with pre-vaccination titer ≥1:10.6

Back to top

Fluzone High-Dose vaccine safety profile

Frequency of solicited systemic adverse events (AEs) and injection site reactions within 7 days post-vaccination6

Chart: Frequency of solicited systemic adverse events (AEs) and injection site reactions within 7 days post-vaccination

c N = Number of subjects with available data for events listed.

Solicited injection site reactions and systemic adverse events were more frequent after vaccination with Fluzone High-Dose vaccine compared to Fluzone vaccine in adults 65 years of age and older.6

Back to top

PLEASE NOTE

By clicking on this link, you will be leaving this Sanofi Pasteur website and going to another, entirely independent website. Sanofi Pasteur provides this link as a service to its website visitors; however, it takes no responsibility for the information presented on any website but its own.

This link has opened in a new window. To return to your original site, please close this new window.

Click here to go to the page you requested. Click here to close this window and return to the site.

PLEASE NOTE

By clicking on this link, you will be leaving this Sanofi Pasteur website and going to another Sanofi Pasteur website.

This link has opened in a new window. To return to your original site, please close this new window.

Click here to go to the page you requested. Click here to close this window and return to the site.